A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus

ID Number 16-1123

Principal Investigator(s)
Matthew Galsky

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to test the effectiveness (how well the drug works), safety and tolerability of an investigational drug called nivolumab (also known as BMS-936558).  Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow the body's immune system to work against tumor cells.  The effectiveness of nivolumab in cancer of the bladder and other parts of the urinary system (ureter and renal pelvis) will be assessed by measuring disease-free survival.

Contact Information
Kiev Gimpel-Tetra
(212) 824-7309

Recruiting Patients: Yes